Category: 3. Business

The team is now planning to build a bigger space factory – one that could make semiconductor material for 10,000 chips.

They also need to test the technology to bring the material back to Earth.

On a future mission, a heat shield named Pridwen after the legendary shield of King Arthur will be deployed to protect the spacecraft from the intense temperatures it will experience as it re-enters the Earth’s atmosphere.

Other companies are also looking skywards – to make everything from pharmaceuticals to artificial tissues.

“In-space manufacturing is something that is happening now,” says Libby Jackson, head of space at the Science Museum.

“It’s the early days and they’re still showing this in small numbers at the moment.

“But by proving the technology it really opens the door for an economically viable product, where things can be made in space and return to Earth and have use and benefit to everybody on Earth. And that’s really exciting.”

Emory Decatur Hospital is home to one of Emory’s longest-running clinical educational programs — the Emory School of Medicine Radiologic Technology (RT) Certificate Program. Founded in 1962, the certificate program prepares entry-level radiologic technologists to fill high-demand jobs and meet the critical clinical imaging needs of the greater Atlanta community.

The RT Certificate Program is part of the allied health program offerings through the Emory School of Medicine. Emory Decatur Hospital serves as the off-campus instructional site for the program.

Radiologic technology involves using X-rays or radioactive substances for medical diagnostic and therapeutic purposes. Those who use the technology are known as radiologic technologists, or radiographers. They specialize in using X-rays to create images of the body and perform diagnostic procedures including imaging the skeletal system, chest and abdomen.

The Emory School of Medicine Radiologic Technology Certificate Program is a full-time, 24-month long program that accepts between 19 and 25 students each year, with space for up to 50 total. Students train in areas such as general X-ray, trauma imaging and fluoroscopy, and also rotate through specialty areas such as CT (computed tomography), MRI (magnetic resonance imaging) and mammography to enhance their clinical education experience.

“The Emory School of Medicine Radiologic Technology Certificate Program has been a leader in imaging education on a continuous basis for over 60 years,” says Jen Schuck, CEO of Emory Decatur, Emory Hillandale and Emory Long-Term Acute Care hospitals. “I’m proud that the program is a leader in creating career opportunities for people in our community and ensuring that graduates are well-prepared to make a real impact in health care.”

Program graduates take the national certification exam for radiography through the American Registry of Radiologic Technologists and upon passing, become registered technologists in radiography. About 70% of graduates accept jobs at Emory Healthcare within a year of finishing the program. To date, approximately 1,100 have graduated from the program.

“From the start, our students are placed in fast-paced health care settings where they use advanced equipment, care for patients from all backgrounds and learn to adapt to the changing needs of the medical field,” says LaShaun Taylor, RTR, program director. “By operating at Emory Decatur Hospital, our program students get hands-on training in a busy medical imaging department, giving graduates an advantage when pursuing their careers.”

The Emory School of Medicine Radiologic Technology Certificate Program has maintained a strong track record of placing graduates in jobs and establishing collaborations to help elevate career advancement. While the program requires participants to hold, at a minimum, an associate degree before beginning the Emory program, it is currently exploring new opportunities to assist students in earning an associate’s degree. The program is also building stronger connections with Emory’s Medical Imaging B.S. Bridge Program as a pathway for program graduates to earn a bachelor’s degree to help advance future career opportunities.

Applications are accepted each year from Sept.1 to March 1. To learn more, visit the Emory School of Medicine Radiologic Technology Certificate Program website.

About Emory Decatur Hospital
Emory Decatur Hospital, one of 11 Emory Healthcare hospitals, is a 451-bed facility located on North Decatur Road in Decatur, Georgia. Emory University School of Medicine faculty, private practice physicians and Emory Specialty Associates physicians care for patients at Emory Decatur, along with more than 2,500 staff. Services include emergency medicine, oncology, heart and vascular care including stroke, maternity care, orthopaedics, behavioral health, a weight loss center and a medical fitness center, among others.

About Emory School of Medicine Education Programs
Emory School of Medicine prepares future health care leaders through innovative education programs, including MD, DPT, PhD, and allied health degrees, as well as residencies, fellowships and continuing education. With a focus on excellence, compassion and discovery, Emory combines the science of medicine with the art of healing to advance patient care and medical research. Learn more at med.emory.edu/education.

Millions of discounted train tickets for half-term activities, weekend getaways and commuting will be up for grabs next week. The week-long Great British Rail Sale, running from 6 to 12 January 2026, will give passengers the chance to save well over 50% on many advance and off-peak tickets.

The reduced fares can be used to travel on thousands of popular routes between 13 January and 25 March 2026. Nearly all train operators are taking part, with routes spanning the length and breadth of Britain.

For those looking to visit museums or schedule meetings in the capital, £10 journeys are on offer from south coast destinations like Portsmouth to London Waterloo – that’s a 59% saving. Or for those planning a quick getaway abroad, journeys from Manchester Piccadilly to Manchester Airport will cost just £1.20, down from £2.90.

The sale comes as the government eases the cost of living for hard-working people by freezing rail fares for the first time in 30 years.

The government is also bringing in major reform to Britain’s rail services by establishing Great British Railways (GBR) – the new, nationalised organisation to run the railway. GBR will bring together 17 different organisations under a single directing mind, cutting through bureaucracy to deliver a rail network that passengers can rely on and be proud of.

Transport Secretary, Heidi Alexander, said:

The Rail Sale is back – and it means further discounts for passengers as we freeze rail fares for the first time in 3 decades to help ease the cost of living.

We all want to see cheaper rail travel, so whether you’re planning a half-term getaway, or visiting friends or family, this sale offers huge reductions.

It’s all part of our plans to build a railway owned by the public, that works for the public.

This is the fourth year of the Rail Sale, with last year’s sale saving passengers around £8 per journey. Last year, over 1 million tickets were sold, bringing in over £9 million in ticket sale revenue for the industry. 

Travelling by train remains one of the quickest and greenest ways to get around, with the government committed to getting more people onto the railways, cutting carbon emissions and freeing up vital space on our roads for emergency services and freight.

Jacqueline Starr, Executive Chair and CEO of Rail Delivery Group, said:

The Rail Sale gives people even more reasons to choose rail, whether it’s reconnecting with loved ones or exploring new places. Rail continues to play a vital role in the lives of millions, supporting local economies and offering a more sustainable way to travel.

This year’s Rail Sale will offer millions of discounted advance fares across the network from 6 January, giving customers the chance to save on journeys big and small. By making rail travel more accessible, we hope even more people will enjoy the convenience and comfort of travelling by rail.

Patricia Yates, CEO of VisitBritain, said:

The new year provides the perfect opportunity to hop onto a train and explore Britain’s great tourism treasures sustainably, boosting the economy by supporting our fantastic visitor experiences and attractions.

Whether it’s a cultural break in one of our vibrant regional cities, a set jetting stay at a world-famous filming backdrop or the friendly welcome from our picturesque coastal and rural destinations, Britain has something for everyone to enjoy, creating memories of a lifetime for visitors.

Key discounts

Journey	Sale price	Full price	Saving
St Pancras to Whitstable	£7.50	£15.10	50%
St Pancras to Canterbury	£8.10	£16.20	50%
Exeter to London Waterloo	£10.00	£41.70	76%
Portsmouth to London Waterloo	£10.00	£24.60	59%
Manchester Piccadilly to Manchester Airport	£1.20	£2.90	59%
Blackpool North to Manchester Piccadilly	£3.50	£7.90	56%
Bolton to Manchester Piccadilly	£1.00	£2.50	60%
Liverpool Lime Street to Wigan North Western	£1.60	£3.70	57%
Newcastle to Middlesbrough	£2.00	£5.20	62%
London Marylebone to Birmingham Moor Street	£7.00	£14.00	50%
Nottingham to London Terminals	£23.00	£46.00	50%
Sheffield to London Terminals	£25.50	£51.00	50%
Charing Cross to Tunbridge Wells	£4.00	£8.10	51%
Ashford International to Ramsgate	£2.70	£5.40	50%

Manitoba Hydro rates will rise four per cent on Jan. 1 as part of an interim general rate hike the Public Utilities Board says it has ordered “on an urgent basis because of a severe drought.”

The province’s independent energy regulator ordered Hydro to raise all of its rates except for diesel charges in 2026 at the maximum allowable annual increase, even though the provincial Crown corporation only sought the first of three consecutive annual rate hikes of 3.5 per cent.

“The increase is necessary, on an urgent basis, to protect the financial health of Manitoba Hydro in light of the current drought,” the Public Utilities Board stated in an order published Tuesday afternoon.

“Water inflows into Manitoba Hydro’s watershed are currently near the second-lowest level in 112 years.”

When Manitoba Hydro filed an application for three annual rate hikes of 3.5 per cent, it was expecting a net income of $218 million for the fiscal year that ends on March 31, 2026, the PUB noted in its order.

Now, Hydro expects to lose $409 million during this fiscal year, which represents “a deterioration” of $625 million, the PUB stated.

The board stated it may adjust this increase in a final rate order for Manitoba Hydro’s next three fiscal years. That final order is expected in March 2026, the board stated.

Rate hike will prove challenging: consumers group

In March, when Manitoba Hydro filed sought permission for three annual rate hikes — a compound rate hike of nearly 11 per cent by 2028 — the Crown corporation said it needed the additional funds in order to fix aging infrastructure, increase generating capacity and mitigate the effects of both drought and debt.

In its application to the Public Utilities Board, Hydro said it must spend $31 billion over the next two decades to improve the reliability of its existing infrastructure and expand its capacity to generate electricity to avoid the possibility of winter power shortages.

Some of the infrastructure along Bipole I and Bipole II, two of Hydro’s three main transmission lines, is more than 50 years old, which is “one to three decades past the industry expected service life,” and will alone requires billions worth of upgrades in the coming decades, the corporation wrote in its rate application.

The Consumers Coalition, which represents four Manitoba non-profit organizations, said in a statement a four per cent Hydro rate hike is understandable given the drought conditions but will still prove challenging for many ratepayers.

This fall, the coalition asked the PUB to set a rate hike below 3.5 per cent this year because Hydro failed to show it’s making difficult choices in the face of drought, coalition lawyer Katrine Dilay said.

“Hydro’s costs continue to escalate at rates well above the rate of inflation, and our clients strongly believe Hydro must examine its own costs before seeking increases from its customers,” Dilay said in a statement.

Hydro spokesperson Peter Chura said the four per cent rate hike will cost the average Manitoba household that only uses electricity as a power source an additional $50.40 in 2026, compared to an additional $44.28 for a 3.5 per cent hike.

Chura said the four per cent increase will cost the average Manitoba household that uses electricity for power and to heat their home an additional $96.60 this coming year, compared to an additional $84.60 for a 3.5 per cent increase.

Urgent rate hike follows ‘rate freeze’

Hydro did not seek a rate hike at all for 2025 in a move the NDP government called a “rate freeze.” Dilay and the Progressive Conservative Opposition criticized the decision to forgo additional revenue because of the financial pressures facing the Crown corporation, which is also carrying $25.3 billion in debt.

Drought conditions across the Lake Winnipeg watershed preceded the “rate freeze” and are continuing this winter.

According to Manitoba Infrastructure, the water level on Lake Winnipeg on Monday stood at 712.1 feet above sea level, which is below the water level on this date during 90 per cent of the years since 1981.

Adrien Sala, the minister responsible for Manitoba Hydro, said in a statement the NDP government respects the role the PUB plays “in setting fair rates that maintain Hydro’s affordability while keeping the utility strong through wet and dry years.”

On Instagram, PC Leader Obby Khan taunted the NDP for the rate hike.

“So much for your rate freeze,” the Opposition leader wrote.

KARACHI:

Gold prices in Pakistan declined sharply on Tuesday, tracking losses in the international bullion market amid profit-taking following a strong year-end rally.

In the local market, the price of gold per tola dropped by Rs10,700 to settle at Rs459,462, according to rates released by the All-Pakistan Gems and Jewellers Sarafa Association (APGJSA). Similarly, the price of 10-gram gold fell by Rs9,174 to Rs393,914. Silver prices also came under pressure in the local market, with the price per tola falling by Rs145 to Rs7,930. Despite the day’s correction, silver has remained one of the strongest-performing assets this year, reflecting exceptional gains in international markets.

Internationally, precious metals rebounded late Tuesday after suffering sharp losses in the previous session, as investors refocused on geopolitical tensions and broader economic risks. According to Reuters, spot gold rose 0.9% to $4,369.59 per ounce by late afternoon, after recording its biggest single-day percentage decline since October 21 on Monday. The metal had touched a record high of $4,549.71 last week before retreating on profit-taking.

Silver, meanwhile, hit an all-time high of $83.62 per ounce on Monday, marking a surge of around 161% during 2025, before easing back. Platinum and palladium also showed signs of recovery after suffering record declines earlier.

Market participants are closely watching the release of the US Federal Reserve’s December meeting minutes, due at 1900 GMT, for clues on the future path of interest rates, which could influence precious metals prices.

Adnan Agar, Director at Interactive Commodities, said the market appeared relatively stable after recent turbulence.

Agar added that while prices have bounced back modestly, some pressure remains unless gold and silver move decisively towards their recent highs. He also pointed out that international markets are likely to remain subdued in the coming days due to the New Year holiday. “Volatility may persist until around January 10 to 15. After that, markets are expected to cool down. The one-way rally seen in December is unlikely to continue; instead, prices may move both up and down, but with greater stability,” he said.

Meanwhile, the rupee edged up slightly against the US dollar in the inter-bank market on Monday, closing at 280.16, continuing its modest weekly gain from 280.25 to 280.17, according to the State Bank of Pakistan (SBP).

WASHINGTON, Dec. 30, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic response that affects a substantial portion of the population and has long been recognized as a factor affecting military operational readiness.

“This approval underscores the strong scientific evidence in the antiemetic effects of NEREUS™ in motion sickness,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals. “For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options. We are proud of this historic milestone and grateful to the Vanda researchers, patients, investigators, and regulators who contributed to this achievement.”

The efficacy of NEREUS™ is supported by robust data from three pivotal clinical trials—two Phase 3 real-world provocation studies conducted on boats (Motion Syros and Motion Serifos) and one additional supporting study—with participants who had documented histories of motion sickness. In Motion Syros (n=365), vomiting incidence was 18.3–19.5% with NEREUS™ versus 44.3% with placebo (p<0.0001).¹ In Motion Serifos (n=316), vomiting rates were 10.4–18.3% with NEREUS™ versus 37.7% with placebo (p≤0.0014), representing risk reductions of over 50–70%.² Across the pivotal program, NEREUS™ consistently demonstrated significant reductions in vomiting and a favorable safety profile consistent with acute use.

Motion sickness has been recognized as a critical factor in military operations since World War II, most notably during the D-Day invasion of Normandy in 1944, where severe seasickness impaired the effectiveness of troops, including paratroopers of the 101st Airborne Division deployed in rough Channel crossings and airborne drops. The condition was elevated to a strategic imperative, prompting early research into antiemetic therapies to ensure operational readiness during large-scale troop deployments by sea, air, and land.

Today, motion sickness remains prevalent in civilian life, with approximately 25–30% of adults³—roughly 65–78 million people in the U.S.—experiencing symptoms during common travel modes such as cars, planes, or boats. Globally, up to one-third of individuals are highly susceptible.⁴ While most cases are mild, an estimated 5–15% of the population experiences severe, recurrent symptoms that can significantly impact quality of life. This severe segment comprises two key groups: those whose illness is inadequately controlled by existing therapeutic options, leaving them with persistent debilitating symptoms despite treatment, and those whose illness is so severe that it leads to avoidance of engaging in motion-provoking activities altogether, resulting in altered travel plans, missed opportunities, or complete abstention from certain modes of transportation or experiences. Tens of millions seek pharmacologic treatment annually, primarily through over-the-counter options, though many patients opt for prescription therapies when escalating care. Motion sickness arises from a sensory conflict between visual, vestibular, and proprioceptive inputs, triggering the release of substance P and activation of NK-1 receptors in the central nervous system, leading to nausea and vomiting. NEREUS™’s mechanism of action—potent and selective antagonism of NK-1 receptors—directly addresses this pathway.

The approval of NEREUS™ for the prevention of vomiting induced by motion validates its pharmacological profile and paves the way for further exploration of NK-1 antagonism in related vomit-inducing conditions. Vanda is advancing tradipitant in clinical development for gastroparesis, a chronic disorder characterized by delayed gastric emptying and persistent nausea/vomiting, as well as for the prevention of nausea and vomiting induced by GLP-1 receptor agonists—a common side effect impacting adherence in the rapidly growing obesity and diabetes treatment landscape. 

Vanda anticipates launching NEREUS™ for the prevention of vomiting induced by motion in the coming months and remains committed to expanding its therapeutic potential across indications driven by substance P-mediated pathways.

References

1. Polymeropoulos VM, Kiely L, Bushman ML, Sutherland EB, Goldberg AR, Pham AX, Miller CR, Mourad R, Davis TR, Pham NV, Morgan DB, Giles AK, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025 Mar 4;16:1550670. doi: 10.3389/fneur.2025.1550670. PMID: 40103934; PMCID: PMC11913704, available here.
2. Vanda Pharmaceuticals Inc., “Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness” [Press Release], May 16, 2024, available here.
3. Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999: 42: 444-461, available here.
4. Golding, J. F. (2016). “Motion sickness”. Neuro-Otology. Handbook of Clinical Neurology. Vol. 137. pp. 371–390. doi:10.1016/B978-0-444-63437-5.00027-3. ISBN 978-0-444-63437-5. ISSN 0072-9752. PMID 27638085, available here.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About NEREUS™

NEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. NEREUS™ is approved for the acute prevention of vomiting induced by motion in adults, and is currently in clinical development for a variety of indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

NEREUS™ is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults.

Important Safety Information

In placebo-controlled clinical trials, somnolence (6%, 12%) and fatigue (6%, 8%) were adverse reactions reported in subjects who took a single dose of 85 mg or 170 mg NEREUS™, respectively. NEREUS™ may impair the mental and/or physical abilities required for driving a motor vehicle or operating heavy machinery. Concomitant use of other drugs that cause central nervous system depression and strong CYP3A4 inhibitors may increase this effect. If concomitant use is unavoidable, warn patients against driving and other activities requiring complete mental alertness.

Available data from clinical trials with NEREUS™ use in pregnant women are insufficient to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Lactation studies have not been conducted to assess the presence of tradipitant or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Tradipitant has been found to be present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Monitor breastfed infants for somnolence.

The safety and effectiveness of NEREUS™ have not been established in pediatric patients. 

Tradipitant has not been studied in subjects with severe renal impairment (eGFR ≤ 29 mL/min/1.73m2). Avoid use of NEREUS™ in patients with severe renal impairment.

Tradipitant has not been studied in patients with any degree of hepatic impairment (Child-Pugh Class A to C). Avoid NEREUS™ in patients with mild, moderate, or severe hepatic impairment.

CONTRAINDICATIONS

None.

DRUG INTERACTIONS

Tradipitant is a CYP3A4 substrate. Strong CYP3A4 inhibitors may increase tradipitant exposure, which may increase the risk of adverse reactions to NEREUS™.

Full Nereus™ Prescribing Information can be found at: https://www.nereus.us.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to statements regarding patient access to NEREUS™, the prevalence of motion sickness, Vanda’s further clinical development plans for NEREUS™, Vanda’s commercial launch plans for NEREUS™ and the timing thereof, and Vanda’s plans to expand the therapeutic potential of NEREUS™ across additional indications driven by substance P-mediated pathways are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s ability to successfully execute the commercial launch of NEREUS™ in the coming months, the accuracy of the estimates of the prevalence of motion sickness, Vanda’s ability to continue to advance tradipitant in gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists, and Vanda’s ability to develop NEREUS™ as a safe and effective treatment for additional indications driven by substance P-mediated pathways. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]

SOURCE Vanda Pharmaceuticals Inc.

Iron ore futures prices declined on Tuesday, as increased shipments from major suppliers Australia and Brazil weighed on sentiment, although lingering hopes of steelmakers in top consumer China restocking cargoes limited the loss.

The most-traded May iron ore contract on China’s Dalian Commodity Exchange (DCE) TIO1! closed trade 0.44% lower at 789 yuan ($112.86) a metric ton. The contract touched its highest level since December 3 on Monday.

The benchmark January iron ore (SZZFF6) on the Singapore Exchange was 0.17% lower at $105.65 a ton by 0717 GMT. It hit its highest level since November 27 at $106.55 in Monday’s session.

Iron ore shipments from Australia and Brazil, the world’s two-largest suppliers, rose 8.6% week-on-week during December 22-28, data from consultancy Mysteel showed.

Chinese steel mills are expected to book more cargoes in the coming weeks to meet production needs over the week-long Lunar New Year holiday break in February, said analysts.

Meanwhile, Chinese developer Vanke’s 000002 bondholders approved its proposal to extend the grace period for the repayment of a 3.7 billion yuan bond, temporarily removing a default risk.

The property market was the largest steel consumer in China, but protracted woes in the sector hit steel consumption, weighing on prices of steel and the feedstocks.

Other steelmaking ingredients on the DCE gained ground, with coking coal NYMEX:ACT1! and coke (DCJcv1) up 0.99% and 0.44%, respectively.

Steel benchmarks on the Shanghai Futures Exchange moved sideways. Rebar RBF1! lost 0.1% and hot-rolled coil EHR1! nudged down 0.33%. Stainless steel HRC1! firmed 1.28% and wire rod gained 0.32%.
Source: Reuters